Table 2 Respondents views on trial design
From: The attitude of patients with progressive ataxias towards clinical trials
|  | FRDA all (%) | FRDA trial naive (n = 59) (%) | FRDA one trial (n = 49) (%) | FRDA multiple trials (n = 61) (%) | Inherited CA (%) | Idiopathic CA (%) |
|---|---|---|---|---|---|---|
Respondents who are trial experienced | 63.9 | Â | Â | Â | 12.7 | 4.5 |
Respondents very or extremely interested in participating in a future clinical trial | 73.9 | 70.1 | 67.3 | 86.7 | 65.2 | 59.2 |
Respondents very or extremely interested in participating in a future clinical trial (drug repurposing) | 75.2 | 74.1 | 73.4 | 81.9 | 53.1 | 50.9 |
Respondents willing to participate in phase of trial | Â | Â | Â | Â | Â | Â |
 Phase 1 | 57.4 | 50.8 | 48.9 | 60.6 | 68.3 | 65.3 |
 Phase 2 | 89.5 | 69.4 | 87.7 | 91.8 | 75.6 | 85.7 |
 Phase 3 | 77.1 | 69.4 | 55.9 | 77 | 78 | 40.8 |
Respondents very or extremely likely to participate in a future trial if they might be given a placebo | 59.5 | 53.3 | 60.4 | 69.3 | 48.9 | 44.4 |
Respondents who would be very or extremely more willing to join a trial if an open label extension phase was offered | 68.6 | 59.6 | 83.6 | 69.3 | 47.8 | 37.7 |
Respondents who felt it is either very or extremely important to have the results of a trial they participated in relayed back to them | 84.5 | 87.1 | 87.5 | 83.3 | 81.3 | 78 |